Aspirin use is associated with increased risk for incident heart failure: a patient‐level pooled analysis

Autor: Lutgarde Thijs, Fang-Fei Wei, Blerim Mujaj, Peter S. Sever, Zhenyu Zhang, Javed Butler, John G.F. Cleland, Faiez Zannad, Peter Verhamme, Wen-Yi Yang, Roberto Latini, Heart Omics in Ageing Investigators, Christian Delles, Jan A. Staessen
Přispěvatelé: Department of Cardiovascular Sciences [Leuven], Catholic University of Leuven - Katholieke Universiteit Leuven (KU Leuven), University of Freiburg [Freiburg], University of Glasgow, University of Mississippi Medical Center (UMMC), Imperial College London, IRCCS - Istituto di Ricerche Farmacologiche 'Mario Negri', Cardiology Department, Castle Hill Hospital, University of Hull, University of Hull [United Kingdom], Défaillance Cardiovasculaire Aiguë et Chronique (DCAC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Centre d'investigation clinique plurithématique Pierre Drouin [Nancy] (CIC-P), Centre d'investigation clinique [Nancy] (CIC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Cardiovascular and Renal Clinical Trialists [Vandoeuvre-les-Nancy] (INI-CRCT), Institut Lorrain du Coeur et des Vaisseaux Louis Mathieu [Nancy], French-Clinical Research Infrastructure Network - F-CRIN [Paris] (Cardiovascular & Renal Clinical Trialists - CRCT ), Research Institute Alliance for the Promotion of Preventive Medicine (APPREMED), The European Union (HEALTH-F7-305507 HOMAGE), the European Research Council (Advanced Researcher Grant 2011-294713-EPLORE), the European Research Council (Proof-of-Concept Grant 713601-uPROPHET), and the European Research Area Net for Cardiovascular Diseases(JTC2017-046-PROACT) supported the Research Unit Hypertension and Cardiovascular Research. The Non-Profit Association Alliance for the Promotion of Preventive Medicine (APPREMED, URL, http://www.appremed.org), Mechelen, Belgium, received a nonbinding grant fromOMRON Healthcare, Co, Ltd, Kyoto, Japan., European Project: 305507,EC:FP7:HEALTH,FP7-HEALTH-2012-INNOVATION-1,HOMAGE(2013), European Project: 294713,EC:FP7:ERC,ERC-2011-ADG_20110310,EPLORE(2012), European Project, BOZEC, Erwan, Heart OMics in AGEing - HOMAGE - - EC:FP7:HEALTH2013-02-01 - 2019-01-31 - 305507 - VALID, EPidemiological Left ventriclar Outcomes Research in Europe - EPLORE - - EC:FP7:ERC2012-07-01 - 2017-06-30 - 294713 - VALID, 713601-uPROPHET - INCOMING, JTC2017-046-PROACT - INCOMING
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Percentile
Cardiac & Cardiovascular Systems
Health Status
BLOOD-PRESSURE
Disease
030204 cardiovascular system & hematology
0302 clinical medicine
DESIGN
Medicine
030212 general & internal medicine
Clinical Trials as Topic
Aspirin
Primary prevention
Incidence (epidemiology)
Secondary prevention
Hazard ratio
LOW-DOSE ASPIRIN
3. Good health
[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system
Cardiovascular diseases
Original Article
Cardiology and Cardiovascular Medicine
Life Sciences & Biomedicine
medicine.drug
medicine.medical_specialty
STRATEGIES
Aspirin use
Heart failure
WARFARIN
03 medical and health sciences
[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system
Internal medicine
Diseases of the circulatory (Cardiovascular) system
Humans
CARDIOVASCULAR EVENTS
Aged
Science & Technology
business.industry
MORTALITY
Original Articles
medicine.disease
RANDOMIZED-TRIAL
DYSFUNCTION
Confidence interval
RC666-701
Cardiovascular System & Cardiology
Observational study
business
Zdroj: ESC Heart Failure
ESC Heart Failure, 2021, ⟨10.1002/ehf2.13688⟩
ESC Heart Failure, Wiley, 2021, ⟨10.1002/ehf2.13688⟩
ESC Heart Failure, Vol 9, Iss 1, Pp 685-694 (2022)
ISSN: 2055-5822
Popis: AIMS: Recent trials evaluating the effect of aspirin in the primary prevention of cardiovascular disease showed little or no benefit. However, the role of aspirin on the risk of incident heart failure (HF) remains elusive. This study aimed to evaluate the role of aspirin use on HF incidence in primary and secondary prevention and whether aspirin use increases the risk of incident HF in patients at risk. METHODS AND RESULTS: Data from 30 827 patients at risk for HF enrolled in six observational studies were analysed [women 33.9%, mean age (±standard deviation) 66.8 ± 9.2 years]. Cardiovascular risk factors and aspirin use were recorded at baseline, and patients were followed up for the first incident of fatal or non-fatal HF. The association of incident HF with aspirin use was assessed using multivariable-adjusted proportional hazard regression, which accounted for study and cardiovascular risk factors. Over 5.3 years (median; 5th-95th percentile interval, 2.1-11.7 years), 1330 patients experienced HF. The fully adjusted hazard ratio (HR) associated with aspirin use was 1.26 [95% confidence interval (CI) 1.12-1.41; P ≤ 0.001]. Further, in a propensity-score-matched analysis, the HR was 1.26 (95% CI 1.10-1.44; P ≤ 0.001). In 22 690 patients (73.6%) without history of cardiovascular disease, the HR was 1.27 (95% CI 1.10-1.46; P = 0.001). CONCLUSIONS: In patients, at risk, aspirin use was associated with incident HF, independent of other risk factors. In the absence of conclusive trial evidence, our observations suggest that aspirins should be prescribed with caution in patients at risk of HF or having HF. ispartof: ESC HEART FAILURE vol:9 issue:1 pages:685-694 ispartof: location:England status: published
Databáze: OpenAIRE
Externí odkaz: